Aster DM Healthcare
- Market cap
- ₹ 56,817 Cr.
- P/E
- 161.7x
- P/B
- 7.4x
- 52-week range
- 519.1 – 891.3
- ROE
- 11%
- ROCE
- 11%
- Dividend yield
- 0.5%
- Debt / equity
- 0.49
- Sector
- Healthcare Services
- Industry
- Hospital
- Listed on
- NSE, BSE
About
Aster DM Healthcare Limited is an India-based healthcare service provider. The Company is operating in India with a presence across primary, secondary, tertiary, and quaternary healthcare through approximately 19 hospitals with 5,159 beds, 10 clinics, 203 pharmacies (Operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster), and 262 labs and patient experience centers across five states in India. Its center of excellence includes Cardiac Sciences, Neurosciences, Gastro Sciences, Orthopaedics, Multi-Organ Transplant. Its pharmacy offers operating 203 pharmacies across southern India, delivering quality pharmaceutical, nutritional, infant care, lifestyle, and wellness products to communities and expanding healthcare access. Its labs deliver diagnostic services covering Biochemistry, Microbiology, Hematology, Clinical Pathology, Histopathology and Cytogenetics.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Hospital: 41 companies →Aster DM Healthcare against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)161.7 against a typical 48.9: pricier than most peers (1st = cheapest).38th of 40
- Sales growth+21.6% against a typical +21.1% from a year earlier.17th of 34
- Profit growth−69.1% against a typical +13% from a year earlier.27th of 31
- Share price, 3 months−17.8% against a typical −10.9%.23rd of 34
- Size₹ 56,817.2 Cr. market value against a typical ₹ 1,306.7 Cr. (1st = largest).4th of 36
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety, with caution
Rated AA+ to A+ by 2 agencies- The agencies don't fully agree: CRISIL says AA+, ICRA says A+.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil AA+ | Stable | 29 Jul 2026 |
| ICRA | [ICRA]A+ Rating Watch with Positive Implications | — | 3 Oct 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 29 Jul 2026 | New rating | Crisil AA+ | — | CRISIL | ₹ 860.5 Cr. | |
| 3 Oct 2025 | Reaffirmed | [ICRA]A+ Rating Watch with Positive Implications | — | ICRA | ₹ 602 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Aug 2026 | Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2026 |
| 30 Apr 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 26 Mar 2026 | Dividend | To consider interim dividend for the Financial Year 2025-26 |
| 30 Jan 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 6 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and adoption of Aster DM Healthcare Limited Employee Stock Option Scheme - 2025 |
| 30 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 929 | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 | 1,186 | 1,182 | 1,311 |
| Expenses | 787 | 805 | 817 | 841 | 869 | 864 | 818 | 876 | 961 | 983 | 958 | 1,055 |
| Operating Profit | 142 | 149 | 156 | 161 | 217 | 186 | 182 | 202 | 236 | 202 | 224 | 256 |
| OPM % | 15% | 16% | 16% | 16% | 20% | 18% | 18% | 19% | 20% | 17% | 19% | 20% |
| Other Income | −64 | 153 | −40 | 5,120 | 35 | 9 | 5 | 29 | 28 | 0 | 37 | −77 |
| Interest | 30 | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 | 31 | 30 | 31 |
| Depreciation | 54 | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 | 68 | 67 | 69 |
| Profit before tax | −7 | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 | 167 | 103 | 163 | 78 |
| Tax % | 120% | 5% | 108% | 1% | 33% | 37% | 6% | 31% | 27% | 43% | 6% | 62% |
| Net Profit | −15 | 209 | −2 | 5,152 | 106 | 64 | 86 | 94 | 121 | 59 | 154 | 29 |
| EPS in Rs | −0.62 | 3.59 | −0.48 | 103 | 1.94 | 1.14 | 1.58 | 1.65 | 2.12 | 1.01 | 2.71 | 0.31 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −1%
- 5 Years
- −12%
- 3 Years
- 16%
- TTM
- 16%
- 10 Years
- 48%
- 5 Years
- 23%
- 3 Years
- −1%
- TTM
- 2%
- 10 Years
- —
- 5 Years
- 34%
- 3 Years
- 37%
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 9%
- 3 Years
- 7%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Aster DM Healthcare | ₹ 673.00 | ₹ 56,817 Cr. | 161.7x | 7.4x | 11% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 65.1x | 13.4x | 0% | 0% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 73.1x | 10.1x | 0% | 0% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.3x | 7.2x | 0% | 0% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.6x | 9.2x | 0% | 0% |
| Global Health | ₹ 1,165.00 | ₹ 31,449 Cr. | 68x | 9.5x | 0% | 0% |
Management
- Mandayapurath Azad Moopen
- Executive Chairman of the Board
- Hemish Purushottam
- Compliance Officer, Company Secretary
- Varun Khanna
- Managing Director, Group Executive Director
- Alisha Moopen
- Deputy Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.